Endometrial cancer
Not yet recruitingStudy of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy
Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy
- Disease:Endometrial cancer
- Substances:GSK5733584Paclitaxel+1
Germany- Participants:18–64 years · 65+ years
- Substances:GSK5733584
- Sponsor:Glaxosmithkline Research & Development Limited













